Suchergebnisse - "Gupta, Neeraj"

PubPharm (29)

21

Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma : dose selection for a phase 3 maintenance study

enthalten in: Investigational new drugs | 2016

von Gupta, N. | Labotka, R. | Liu, G. | +2

22

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma : a phase 1 study

enthalten in: Journal of hematology & oncology | 2015

von Gupta, N. | Goh, Y. | Min, C. | +10

23

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

enthalten in: Cancer chemotherapy and pharmacology | 2015

von Gupta, N. | Huh, Y. | Hutmacher, M. | +3

24

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

enthalten in: Investigational new drugs | 2015

von Smith, D. | Kalebic, T. | Infante, J. | +14

25

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib : a population pharmacokinetic analysis

enthalten in: British journal of clinical pharmacology | 2015

von Gupta, N. | Zhao, Y. | Hui, A. | +2

26

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma

enthalten in: Future oncology (London, England) | 2015

von Richardson, P. | Moreau, P. | Laubach, J. | +5

27

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma : an open-label phase 1/2 study

enthalten in: The Lancet. Oncology | 2014

von Kumar, S. | Berdeja, J. | Niesvizky, R. | +16

CommentIn: Lancet Oncol. 2014 Dec;15(13):1417-8. - PMID 25456357

28

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

enthalten in: Blood | 2014

von Kumar, S. | Bensinger, W. | Zimmerman, T. | +9

CommentIn: Blood. 2014 Aug 14;124(7):986-7. - PMID 25124778

29

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

enthalten in: Blood | 2014

von Richardson, P. | Baz, R. | Wang, M. | +11

CommentIn: Blood. 2014 Aug 14;124(7):986-7. - PMID 25124778